• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Spiriva - Articles and news items

Boehringer Ingelheim logo

Asthma: Spiriva® (tiotropium) Respimat® becomes the only LAMA licensed in asthma care

Industry news / 1 October 2014 / Boehringer Ingelheim

Boehringer Ingelheim announced that adult asthma patients could benefit from a new treatment…

Boehringer Ingelheim logo

Asthma: new indication for Spiriva® (tiotropium) Respimat®* in the EU may offer millions of adults a significant advance in asthma care

Industry news / 8 September 2014 / Boehringer Ingelheim

Boehringer Ingelheim announced that the indication for Spiriva® (tiotropium) Respimat®* in asthma has been accepted by the regulatory authorities in the EU…

Boehringer Ingelheim logo

Boehringer Ingelheim to present comprehensive data supporting broad respiratory portfolio in COPD, asthma and IPF at ERS 2014

Industry news / 1 September 2014 / Boehringer Ingelheim

The European Respiratory Society International Congress, in Munich, Germany, September 6-10, 2014 sets the scene for important announcements across the substantial Boehringer Ingelheim respiratory portfolio…

Boehringer Ingelheim logo

Additional results from post-hoc analysis underline effectiveness of SPIRIVA®

Industry news / 20 May 2014 / Boehringer Ingelheim

Data analyses presented at the Annual American Thoracic Society International Conference 2014 reconfirm the efficacy of SPIRIVA® (tiotropium) in reducing the risk of COPD exacerbations…

Boehringer Ingelheim logo

Boehringer Ingelheim submits applications in Europe to extend the indication for the use of tiotropium Respimat® to the treatment of asthma in adults aged 18 years and over

Industry news / 13 November 2013 / Boehringer Ingelheim

“Our extensive studies have demonstrated that tiotropium Respimat® has the potential to be an effective new treatment…”

Professor Antonio Anzueto, Professor of Medicine Pulmonary/Critical Care Medicine, University of Texas Health Science Center at San Antonio, Texas, USA

Landmark TIOSPIRTM trial reinforces importance of SPIRIVA® in both available formulations as the world’s leading maintenance therapy for chronic obstructive pulmonary disease (COPD)

Industry news, News / 9 September 2013 / Boehringer Ingelheim

TIOSPIR™, with over 17,000 COPD patients included and one of the largest international COPD trials ever conducted…

Boehringer Ingelheim logo

SPIRIVA®* celebrates 10 years of ongoing commitment to patients and advancing clinical innovation in COPD

Industry news, News / 3 September 2012 / Boehringer Ingelheim

SPIRIVA® is the most prescribed COPD maintenance treatment worldwide…


Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +